XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Revenue (Tables)

6 Months Ended

Jun. 30, 2024

Revenue [abstract]

Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss

Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
		(EUR’000)								(EUR’000)
Revenue
Sale of commercial products			31,389				35,895				97,888				67,446
Rendering of services			3,740				10,909				8,364				12,079
Sale of clinical supply			—				—				1				254
Licenses			869				589				25,639				1,203
Total revenue			35,998				47,393				131,892				80,982
Attributable to
Commercial customers			31,389				35,895				97,888				67,446
Collaboration partners and license agreements			4,609				11,498				34,004				13,536
Total revenue			35,998				47,393				131,892				80,982
Specified by timing of recognition
Recognized over time			3,740				10,909				8,364				12,079
Recognized at a point in time			32,258				36,484				123,528				68,903
Total revenue			35,998				47,393				131,892				80,982
Specified per geographical area
Europe			5,082				—				6,649				—
North America			29,394				46,758				122,075				79,828
Asia			1,522				635				3,168				1,154
Total revenue			35,998				47,393				131,892				80,982

X

- Definition

Disclosure of segment revenues by destination of major customers explanatory.

+ References

No definition available.

+ Details

Name:	asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory
Namespace Prefix:	asnd_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_RevenueAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration